Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Mackall Website

Crystal L. Mackall, M.D.

Selected Publications

1)  van Den Brink M, Leen AM, Baird K, Merchant M, Mackall C, Bollard CM.
Enhancing immune reconstitution: from bench to bedside.
Biol. Blood Marrow Transplant. 19: S79-83, 2013.
2)  Zhang H, Maric I, Diprima MJ, Khan J, Orentas RJ, Kaplan RN, Mackall CL.
Fibrocytes represent a novel MDSC subset circulating in patients with metastatic cancer.
Blood. 122: 1105-13, 2013.
3)  Brehm C, Huenecke S, Pfirrmann V, Rossig C, Mackall CL, Bollard CM, Gottschalk S, Schlegel PG, Klingebiel T, Bader P.
Highlights of the third international conference on immunotherapy in pediatric oncology.
Pediatr Hematol Oncol. 30: 349-66, 2013.
4)  Lundström W, Highfill S, Walsh ST, Beq S, Morse E, Kockum I, Alfredsson L, Olsson T, Hillert J, Mackall CL.
Soluble IL7Ra potentiates IL-7 bioactivity and promotes autoimmunity.
Proc. Natl. Acad. Sci. U.S.A. 110: E1761-70, 2013.
5)  Haso W, Lee DW, Shah NN, Stetler-Stevenson M, Yuan CM, Pastan IH, Dimitrov DS, Morgan RA, FitzGerald DJ, Barrett DM, Wayne AS, Mackall CL, Orentas RJ.
Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia.
Blood. 121: 1165-74, 2013.
6)  Orentas RJ, Yang JJ, Wen X, Wei JS, Mackall CL, Khan J.
Identification of cell surface proteins as potential immunotherapy targets in 12 pediatric cancers.
Front Oncol. 2: 194, 2012.
7)  Lundström W, Fewkes NM, Mackall CL.
IL-7 in human health and disease.
Semin. Immunol. 24: 218-24, 2012.
8)  Orentas RJ, Lee DW, Mackall C.
Immunotherapy targets in pediatric cancer.
Front Oncol. 2: 3, 2012.
9)  Merchant MS, Geller JI, Baird K, Chou AJ, Galli S, Charles A, Amaoko M, Rhee EH, Price A, Wexler LH, Meyers PA, Widemann BC, Tsokos M, Mackall CL.
Phase I trial and pharmacokinetic study of lexatumumab in pediatric patients with solid tumors.
J. Clin. Oncol. 30: 4141-7, 2012.
10)  Baird K, Fry TJ, Steinberg SM, Bishop MR, Fowler DH, Delbrook CP, Humphrey JL, Rager A, Richards K, Wayne AS, Mackall CL.
Reduced-intensity allogeneic stem cell transplantation in children and young adults with ultrahigh-risk pediatric sarcomas.
Biol. Blood Marrow Transplant. 18: 698-707, 2012.
11)  Lee DW, Barrett DM, Mackall C, Orentas R, Grupp SA.
The future is now: chimeric antigen receptors as new targeted therapies for childhood cancer.
Clin. Cancer Res. 18: 2780-90, 2012.
12)  Zhang H, Cui Y, Voong N, Sabatino M, Stroncek DF, Morisot S, Civin CI, Wayne AS, Levine BL, Mackall CL.
Activating signals dominate inhibitory signals in CD137L/IL-15 activated natural killer cells.
J. Immunother. 34: 187-95, 2011.
13)  Mackall CL, Fry TJ, Gress RE.
Harnessing the biology of IL-7 for therapeutic application.
Nat. Rev. Immunol. 11: 330-42, 2011.
14)  Capitini CM, Gottschalk S, Brenner M, Cooper LJ, Handgretinger R, Mackall CL.
Highlights of the second international conference on.
Pediatr Hematol Oncol. 28: 459-60, 2011.
15)  Mackall CL.
In search of targeted therapies for childhood cancer.
Front Oncol. 1: 18, 2011.
16)  Mackall C.
In Search of Targeted Therapies for Pediatric Cancer.
Frontiers in Pediatric Oncology. 1: 1-5, 2011.
Full Text Article. [Journal]
17)  Du X, Xiang L, Mackall CL, Pastan I.
Killing of Resistant Cancer Cells with Low Bak by a Combination of an Anti-mesothelin Immunotoxin and a TRAIL Receptor 2 Agonist Antibody.
Clin Cancer Res. 17: 5926-34, 2011.
18)  Meadors JL, Cui Y, Chen Q, Song YK, Khan J, Merlino G, Tsokos M, Orentas RJ, Mackall CL.
Murine rhabdomyosarcoma is immunogenic and responsive to T-cell-based immunotherapy.
Pediatr Blood Cancer. 57: 921-9, 2011.
19)  Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME, Wunderlich JR, Nahvi AV, Helman LJ, Mackall CL, Kammula US, Hughes MS, Restifo NP, Raffeld M, Lee CC, Levy CL, Li YF, El-Gamil M, Schwarz SL, Laurencot C, Rosenberg SA.
Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1.
J. Clin. Oncol. 29: 917-24, 2011.
20)  Capitini CM, Mackall CL, Wayne AS.
Immune-based therapeutics for pediatric cancer.
Expert Opin Biol Ther. 10: 163-78, 2010.
21)  Wayne AS, Capitini CM, Mackall CL.
Immunotherapy of childhood cancer: from biologic understanding to clinical application.
Curr. Opin. Pediatr. 22: 2-11, 2010.
22)  Guimond M, Freud AG, Mao HC, Yu J, Blaser BW, Leong JW, Vandeusen JB, Dorrance A, Zhang J, Mackall CL, Caligiuri MA.
In vivo role of Flt3 ligand and dendritic cells in NK cell homeostasis.
J. Immunol. 184: 2769-75, 2010.
23)  Cairo MS, Jordan CT, Maley CC, Chao C, Melnick A, Armstrong SA, Shlomchik W, Molldrem J, Ferrone S, Mackall C, Zitvogel L, Bishop MR, Giralt SA, June CH.
NCI first international workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on the biological considerations of hematological relapse following allogeneic stem cell transplantation unrelated to graft-versus-tumor effects: state of the science.
Biol. Blood Marrow Transplant. 16: 709-28, 2010.
24)  Fewkes NM, Mackall CL.
Novel gamma-chain cytokines as candidate immune modulators in immune therapies for cancer.
Cancer J. 16: 392-8, 2010.
25)  Fewkes NM, Krauss AC, Guimond M, Meadors JL, Dobre S, Mackall CL.
Pharmacologic modulation of niche accessibility via tyrosine kinase inhibition enhances marrow and thymic engraftment after hematopoietic stem cell transplantation.
Blood. 115: 4120-9, 2010.
26)  Sportès C, Babb RR, Krumlauf MC, Hakim FT, Steinberg SM, Chow CK, Brown MR, Fleisher TA, Noel P, Maric I, Stetler-Stevenson M, Engel J, Buffet R, Morre M, Amato RJ, Pecora A, Mackall CL, Gress RE.
Phase I study of recombinant human interleukin-7 administration in subjects with refractory malignancy.
Clin. Cancer Res. 16: 727-35, 2010.
27)  Ahmed N, Heslop HE, Mackall CL.
T-cell-based therapies for malignancy and infection in childhood.
Pediatr. Clin. North Am. 57: 83-96, 2010.
28)  Fry TJ, Shand JL, Milliron M, Tasian SK, Mackall CL.
Antigen loading of DCs with irradiated apoptotic tumor cells induces improved anti-tumor immunity compared to other approaches.
Cancer Immunol. Immunother. 58: 1257-64, 2009.
29)  Mackall C, Fry T, Gress R, Peggs K, Storek J, Toubert A.
Background to hematopoietic cell transplantation, including post transplant immune recovery.
Bone Marrow Transplant. 44: 457-62, 2009.
30)  Wan X, Kim SY, Guenther LM, Mendoza A, Briggs J, Yeung C, Currier D, Zhang H, Mackall C, Li W, Tuan RS, Deyrup AT, Khanna C, Helman L.
Beta4 integrin promotes osteosarcoma metastasis and interacts with ezrin.
Oncogene. 28: 3401-11, 2009.
31)  Capitini CM, Herby S, Milliron M, Anver MR, Mackall CL, Fry TJ.
Bone marrow deficient in IFN-{gamma} signaling selectively reverses GVHD-associated immunosuppression and enhances a tumor-specific GVT effect.
Blood. 113: 5002-9, 2009.
32)  Peggs KS, Krauss AC, Mackall CL.
Clinical implications of immune reconstitution following hematopoietic stem cell transplantation.
Cancer Treat. Res. 144: 1-24, 2009.
33)  Merchant MS, Mackall CL.
Current approach to pediatric soft tissue sarcomas.
Oncologist. 14: 1139-53, 2009.
34)  Capitini CM, Fry TJ, Mackall CL.
Cytokines as Adjuvants for Vaccine and Cellular Therapies for Cancer.
Am J Immunol. 5: 65-83, 2009.
35)  Cui Y, Zhang H, Meadors J, Poon R, Guimond M, Mackall CL.
Harnessing the physiology of lymphopenia to support adoptive immunotherapy in lymphoreplete hosts.
Blood. 114: 3831-40, 2009.
36)  Capitini CM, Cooper LJ, Egeler RM, Handgretinger R, Locatelli F, Sondel PM, Mackall CL.
Highlights of the First International.
J. Pediatr. Hematol. Oncol. 31: 227-44, 2009.
37)  Guimond M, Veenstra RG, Grindler DJ, Zhang H, Cui Y, Murphy RD, Kim SY, Na R, Hennighausen L, Kurtulus S, Erman B, Matzinger P, Merchant MS, Mackall CL.
Interleukin 7 signaling in dendritic cells regulates the homeostatic proliferation and niche size of CD4+ T cells.
Nat. Immunol. 10: 149-57, 2009.
38)  Capitini CM, Chisti AA, Mackall CL.
Modulating T-cell homeostasis with IL-7: preclinical and clinical studies.
J. Intern. Med. 266: 141-53, 2009.
39)  Sportès C, Gress RE, Mackall CL.
Perspective on potential clinical applications of recombinant human interleukin-7.
Ann. N. Y. Acad. Sci. 1182: 28-38, 2009.
40)  Fox E, Widemann BC, Hawkins DS, Jayaprakash N, Dagher R, Aikin AA, Bernstein D, Long L, Mackall C, Helman L, Steinberg SM, Balis FM.
Randomized trial and pharmacokinetic study of pegfilgrastim versus filgrastim after dose-intensive chemotherapy in young adults and children with sarcomas.
Clin. Cancer Res. 15: 7361-7, 2009.
41)  Fitzhugh CD, Wise B, Baird K, Tsokos M, Helman L, Mackall C, Savage SA, Warren KE.
Secondary supratentorial primitive neuroectodermal tumor following treatment of childhood osteosarcoma.
Pediatr Blood Cancer. 53: 496-8, 2009.
42)  Capitini CM, Derdak J, Hughes MS, Love CP, Baird K, Mackall CL, Fry TJ.
Unusual sites of extraskeletal metastases of Ewing sarcoma after allogeneic hematopoietic stem cell transplantation.
J. Pediatr. Hematol. Oncol. 31: 142-4, 2009.
43)  Mackall CL, Rhee EH, Read EJ, Khuu HM, Leitman SF, Bernstein D, Tesso M, Long LM, Grindler D, Merino M, Kopp W, Tsokos M, Berzofsky JA, Helman LJ.
A pilot study of consolidative immunotherapy in patients with high-risk pediatric sarcomas.
Clin. Cancer Res. 14: 4850-8, 2008.
44)  Sportes C, Hakim FT, Memon SA, Zhang H, Chua KS, Brown MR, Fleisher TA, Krumlauf MC, Babb RR, Chow CK, Fry TJ, Engels J, Buffet R, Morre M, Amato RJ, Venzon DJ, Korngold R, Pecora A, Gress RE, Mackall CL.
Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets.
J. Exp. Med. 205: 1701-14, 2008.
45)  Dean RM, Fry T, Mackall C, Steinberg SM, Hakim F, Fowler D, Odom J, Foley J, Gress R, Bishop MR.
Association of serum interleukin-7 levels with the development of acute graft-versus-host disease.
J. Clin. Oncol. 26: 5735-41, 2008.
46)  Kwong KY, Baskar S, Zhang H, Mackall CL, Rader C.
Generation, Affinity Maturation, and Characterization of a Human Anti-Human NKG2D Monoclonal Antibody with Dual Antagonistic and Agonistic Activity.
J. Mol. Biol. 384: 1143-56, 2008.
47)  Reddy P, Arora M, Guimond M, Mackall CL.
GVHD: a continuing barrier to the safety of allogeneic transplantation.
Biol. Blood Marrow Transplant. 15: 162-8, 2008.
48)  Hoffman KE, Derdak J, Bernstein D, Reynolds JC, Avila NA, Gerber L, Steinberg SM, Chrousos G, Mackall CL, Mansky PJ.
Metabolic syndrome traits in long-term survivors of pediatric sarcoma.
Pediatr Blood Cancer. 50: 341-6, 2008.
49)  Guimond M, Leonard WJ, Spolski R, Rossi SW, Veenstra RG, Hollander GA, Mackall CL, Blazar BR.
Thymic stromal lymphopoietin is not necessary or sufficient to mediate the thymopoietic effects of keratinocyte growth factor.
Blood. 111: 969-70, 2008.
50)  Zhang H, Snyder KM, Suhoski MM, Maus MV, Kapoor V, June CH, Mackall CL.
4-1BB is superior to CD28 costimulation for generating CD8+ cytotoxic lymphocytes for adoptive immunotherapy.
J. Immunol. 179: 4910-8, 2007.
51)  Merchant MS, Melchionda F, Sinha M, Khanna C, Helman L, Mackall CL.
Immune reconstitution prevents metastatic recurrence of murine osteosarcoma.
Cancer Immunol. Immunother. 56: 1037-46, 2007.
52)  Hazra R, Jankelevich S, Mackall CL, Avila NA, Wolters P, Civitello L, Christensen B, Jacobsen F, Steinberg SM, Yarchoan R.
Immunologic, virologic, and neuropsychologic responses in human immunodeficiency virus-infected children receiving their first highly active antiretroviral therapy regimen.
Viral Immunol. 20: 131-41, 2007.
53)  Lissat A, Vraetz T, Tsokos M, Klein R, Braun M, Koutelia N, Fisch P, Romero ME, Long L, Noellke P, Mackall CL, Niemeyer CM, Kontny U.
Interferon-gamma sensitizes resistant Ewing's sarcoma cells to tumor necrosis factor apoptosis-inducing ligand-induced apoptosis by up-regulation of caspase-8 without altering chemosensitivity.
Am. J. Pathol. 170: 1917-30, 2007.
54)  Fluur C, De Milito A, Fry TJ, Vivar N, Eidsmo L, Atlas A, Federici C, Matarrese P, Logozzi M, Rajnavolgyi E, Mackall CL, Fais S, Chiodi F, Rethi B.
Potential role for IL-7 in Fas-mediated T cell apoptosis during HIV infection.
J. Immunol. 178: 5340-50, 2007.
55)  Snyder KM, Mackall CL.
Therapy for metastatic ESFT: is it time to ask new questions?.
Pediatric blood & cancer. 49: 115-6, 2007.
56)  Paz-Priel I, Long L, Helman LJ, Mackall CL, Wayne AS.
Thromboembolic events in children and young adults with pediatric sarcoma.
J. Clin. Oncol. 25: 1519-24, 2007.
57)  Shand JC, Mansky PJ, Brown MV, Fleisher TA, Mackall CL.
Adolescents and young adults successfully restore lymphocyte homeostasis after intensive T-cell depleting therapy for cancer.
Br. J. Haematol. 135: 270-1, 2006.
58)  Krupica T, Fry TJ, Mackall CL.
Autoimmunity during lymphopenia: a two-hit model.
Clin. Immunol. 120: 121-8, 2006.
59)  Terabe M, Khanna C, Bose S, Melchionda F, Mendoza A, Mackall CL, Helman LJ, Berzofsky JA.
CD1d-restricted natural killer T cells can down-regulate tumor immunosurveillance independent of interleukin-4 receptor-signal transducer and activator of transcription 6 or transforming growth factor-beta.
Cancer Res. 66: 3869-75, 2006.
60)  Lucas PJ, Kim SJ, Mackall CL, Telford WG, Chu YW, Hakim FT, Gress RE.
Dysregulation of IL-15-mediated T-cell homeostasis in TGF-beta dominant-negative receptor transgenic mice.
Blood. 108: 2789-95, 2006.
61)  Ahmed AA, Nava VE, Pham T, Taubenberger JK, Lichy JH, Sorbara L, Raffeld M, Mackall CL, Tsokos M.
Ewing sarcoma family of tumors in unusual sites: confirmation by rt-PCR.
Pediatr. Dev. Pathol. 9: 488-95, 2006.
62)  Gerber LH, Hoffman K, Chaudhry U, Augustine E, Parks R, Bernad M, Mackall C, Steinberg S, Mansky P.
Functional outcomes and life satisfaction in long-term survivors of pediatric sarcomas.
Archives of physical medicine and rehabilitation. 87: 1611-7, 2006.
63)  van den Broeke LT, Pendleton CD, Mackall C, Helman LJ, Berzofsky JA.
Identification and epitope enhancement of a PAX-FKHR fusion protein breakpoint epitope in alveolar rhabdomyosarcoma cells created by a tumorigenic chromosomal translocation inducing CTL capable of lysing human tumors.
Cancer Res. 66: 1818-23, 2006.
64)  Rosenberg SA, Sportès C, Ahmadzadeh M, Fry TJ, Ngo LT, Schwarz SL, Stetler-Stevenson M, Morton KE, Mavroukakis SA, Morre M, Buffet R, Mackall CL, Gress RE.
IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells.
J. Immunother. 29: 313-9, 2006.
65)  Snyder KM, Mackall CL, Fry TJ.
IL-7 in allogeneic transplant: Clinical promise and potential pitfalls.
Leuk. Lymphoma. 47: 1222-8, 2006.
66)  Crooks GM, Weinberg K, Mackall C.
Immune reconstitution: from stem cells to lymphocytes.
Biol. Blood Marrow Transplant. 12: 42-6, 2006.
67)  Wiener L, Battles H, Bernstein D, Long L, Derdak J, Mackall CL, Mansky PJ.
Persistent psychological distress in long-term survivors of pediatric sarcoma: the experience at a single institution.
Psycho-oncology. 15: 898-910, 2006.
68)  Mansky P, Arai A, Stratton P, Bernstein D, Long L, Reynolds J, Chen D, Steinberg SM, Lavende N, Hoffman K, Nathan PC, Parks R, Augustine E, Chaudhry U, Derdak J, Wiener L, Gerber L, Mackall C.
Treatment late effects in long-term survivors of pediatric sarcoma.
Pediatr Blood Cancer. 2006.
69)  Fry TJ, Mackall CL.
Disis N, eds.
Promising Gamma-c Cytokines for Cancer Immunotherapy: IL7, IL15 and IL21 as Vaccine Adjuvants, Growth Factors and Immunorestoratives. In: Immunotherapy of Cancer.
Human Press; 2005. In Press. [Book Chapter]
70)  Mackall C, Sondel P.
Pizzo P, Poplack D, eds.
Tumor Immunology and Pediatric Cancer. In: Principles and Practice of Pediatric Oncology. Volume 5th Edition.
Philadelphia: Lippincott Williams & Wilkens; 2005. p. 1780 [Book Chapter]
71)  Nathan PC, Tsokos M, Long L, Bernstein D, Wexler LH, Mackall CL, Helman LJ.
Adjuvant chemotherapy for the treatment of advanced pediatric nonrhabdomyosarcoma soft tissue sarcoma: the National Cancer Institute experience.
Pediatr Blood Cancer. 44: 449-54, 2005.
72)  Melchionda F, Fry TJ, Milliron MJ, McKirdy MA, Tagaya Y, Mackall CL.
Adjuvant IL-7 or IL-15 overcomes immunodominance and improves survival of the CD8+ memory cell pool.
J Clin Invest. 115: 1177-87, 2005.
73)  Hakim FT, Memon SA, Cepeda R, Jones EC, Chow CK, Kasten-Sportes C, Odom J, Vance BA, Christensen BL, Mackall CL, Gress RE.
Age-dependent incidence, time course, and consequences of thymic renewal in adults.
J Clin Invest. 115: 930-9, 2005.
74)  Karl JC, Mackall CL.
Cancer therapy-induced immune modulation.
Cancer Chemother Biol Response Modif. 22: 325-41, 2005.
75)  Guimond M, Fry TJ, Mackall CL.
Cytokine signals in T-cell homeostasis.
J Immunother. 28: 289-94, 2005.
76)  Fry TJ, Mackall CL.
Immune reconstitution following hematopoietic progenitor cell transplantation: challenges for the future.
Bone Marrow Transplant. 35 Suppl 1: S53-7, 2005.
77)  Zhang H, Chua KS, Guimond M, Kapoor V, Brown MV, Fleisher TA, Long LM, Bernstein D, Hill BJ, Douek DC, Berzofsky JA, Carter CS, Read EJ, Helman LJ, Mackall CL.
Lymphopenia and interleukin-2 therapy alter homeostasis of CD4+CD25+ regulatory T cells.
Nat Med. 11: 1238-43, 2005.
78)  Fry TJ, Mackall CL.
The many faces of IL-7: from lymphopoiesis to peripheral T cell maintenance.
J Immunol. 174: 6571-6, 2005.
79)  Hazra R, Mackall C.
Thymic function in HIV infection.
Curr HIV/AIDS Rep. 2: 24-8, 2005.
80)  Hazra R, Mackall C.
Thymic function in HIV infection.
Curr HIV/AIDS Rep. 2: 24-8, 2005.
81)  Mackall CL, Velardi A, Hakim FT.
Deeg , Cooke , Ferrara , eds.
The Immune System in Graft-versus-Host Disease: Effector and Target Organ. In: Graft-versus-Host Disease. Volume 3rd Edition.
New York: Marcel Dekker; 2004. p. 195-227 [Book Chapter]
82)  El Kassar N, Lucas PJ, Klug DB, Zamisch M, Merchant M, Bare CV, Choudhury B, Sharrow SO, Richie E, Mackall CL, Gress RE.
A dose effect of IL-7 on thymocyte development.
Blood. 104: 1419-27, 2004.
83)  Al-Shami A, Spolski R, Kelly J, Fry T, Schwartzberg PL, Pandey A, Mackall CL, Leonard WJ.
A role for thymic stromal lymphopoietin in CD4(+) T cell development.
J Exp Med. 200: 159-68, 2004.
84)  Beppu K, Jaboine J, Merchant MS, Mackall CL, Thiele CJ.
Effect of imatinib mesylate on neuroblastoma tumorigenesis and vascular endothelial growth factor expression.
J Natl Cancer Inst. 96: 46-55, 2004.
85)  Melchionda F, McKirdy MK, Medeiros F, Fry TJ, Mackall CL.
Escape from immune surveillance does not result in tolerance to tumor-associated antigens.
J Immunother. 27: 329-38, 2004.
86)  Fry TJ, Sinha M, Milliron M, Chu YW, Kapoor V, Gress RE, Thomas E, Mackall CL.
Flt 3 Ligand Enhances Thymic-Dependent and Thymic-Independent Immune Reconstitution.
Blood. 2004.
87)  Merchant MS, Yang X, Melchionda F, Romero M, Klein R, Thiele CJ, Tsokos M, Kontny HU, Mackall CL.
Interferon gamma enhances the effectiveness of tumor necrosis factor-related apoptosis-inducing ligand receptor agonists in a xenograft model of Ewing's sarcoma.
Cancer Res. 64: 8349-56, 2004.
88)  Bolan CD, Yau YY, Cullis HC, Horwitz ME, Mackall CL, Barrett AJ, Malech HL, Rehak NN, Wayne AS, Leitman SF.
Pediatric large-volume leukapheresis: a single institution experience with heparin versus citrate-based anticoagulant regimens.
Transfusion. 44: 229-38, 2004.
89)  Moniuszko M, Fry T, Tsai WP, Morre M, Assouline B, Cortez P, Lewis MG, Cairns S, Mackall C, Franchini G.
Recombinant interleukin-7 induces proliferation of naive macaque CD4+ and CD8+ T cells in vivo.
J Virol. 78: 9740-9, 2004.
90)  Uren A, Merchant MS, Sun CJ, Vitolo MI, Sun Y, Tsokos M, Illei PB, Ladanyi M, Passaniti A, Mackall C, Toretsky JA.
Beta-platelet-derived growth factor receptor mediates motility and growth of Ewing's sarcoma cells.
Oncogene. 22: 2334-42, 2003.
91)  Fry TJ, Moniuszko M, Creekmore S, Donohue SJ, Douek DC, Giardina S, Hecht TT, Hill BJ, Komschlies K, Tomaszewski J, Franchini G, Mackall CL.
IL-7 therapy dramatically alters peripheral T-cell homeostasis in normal and SIV-infected nonhuman primates.
Blood. 101: 2294-2299, 2003.
92)  Yang X, Merchant MS, Romero ME, Tsokos M, Wexler LH, Kontny U, Mackall CL, Thiele CJ.
Induction of caspase 8 by interferon gamma renders some neuroblastoma (NB) cells sensitive to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) but reveals that a lack of membrane TR1/TR2 also contributes to TRAIL resistance in NB.
Cancer Res. 63: 1122-9, 2003.
93)  Min B, McHugh R, Sempowski GD, Mackall C, Foucras G, Paul WE.
Neonates support lymphopenia-induced proliferation.
Immunity. 18: 131-40, 2003.
94)  Zhang H, Merchant MS, Chua KS, Khanna C, Helman LJ, Telford B, Ward Y, Summers J, Toretsky J, Thomas EK, June CH, Mackall CL.
Tumor expression of 4-1BB ligand sustains tumor lytic T cells.
Cancer Biol Ther. 2: 579-86, 2003.
95)  Khaled AR, Li WQ, Huang J, Fry TJ, Khaled AS, Mackall CL, Muegge K, Young HA, Durum SK.
Bax deficiency partially corrects interleukin-7 receptor alpha deficiency.
Immunity. 17: 561-73, 2002.
96)  Fry TJ, Mackall CL.
Current concepts of thymic aging.
Springer Semin Immunopathol. 24: 7-22, 2002.
97)  Mackall CL.
Enhancing immune reconstitution after stem cell transplants with cytokines.
Cytotherapy. 4: 427-8, 2002.
98)  Mackall CL, Meltzer PS, Helman LJ.
Focus on sarcomas.
Cancer Cell. 2: 175-8, 2002.
99)  Sinha ML, Fry TJ, Fowler DH, Miller G, Mackall CL.
Interleukin 7 worsens graft-versus-host disease.
Blood. 100: 2642-9, 2002.
100)  Fry TJ, Mackall CL.
Interleukin-7 and immunorestoration in HIV: beyond the thymus.
J Hematother Stem Cell Res. 11: 803-7, 2002.
101)  Fry TJ, Mackall CL.
Interleukin-7: from bench to clinic.
Blood. 99: 3892-904, 2002.
102)  Dagher R, Long LM, Read EJ, Leitman SF, Carter CS, Tsokos M, Goletz TJ, Avila N, Berzofsky JA, Helman LJ, Mackall CL.
Pilot trial of tumor-specific peptide vaccination and continuous infusion interleukin-2 in patients with recurrent Ewing sarcoma and alveolar rhabdomyosarcoma: an inter-institute NIH study.
Med Pediatr Oncol. 38: 158-64, 2002.
103)  Merchant MS, Woo CW, Mackall CL, Thiele CJ.
Potential use of imatinib in Ewing's Sarcoma: evidence for in vitro and in vivo activity.
J Natl Cancer Inst. 94: 1673-9, 2002.
104)  Mansky PJ, Liewehr DJ, Steinberg SM, Chrousos GP, Avila NA, Long L, Bernstein D, Mackall CL, Hawkins DS, Helman LJ.
Treatment of metastatic osteosarcoma with the somatostatin analog OncoLar: significant reduction of insulin-like growth factor-1 serum levels.
J Pediatr Hematol Oncol. 24: 440-6, 2002.
105)  Fry TJ, Connick E, Falloon J, Lederman MM, Liewehr DJ, Spritzler J, Steinberg SM, Wood LV, Yarchoan R, Zuckerman J, Landay A, Mackall CL.
A potential role for interleukin-7 in T-cell homeostasis.
Blood. 97: 2983-90, 2001.
106)  Simon RM, Steinberg SM, Hamilton M, Hildesheim A, Khleif S, Kwak LW, Mackall CL, Schlom J, Topalian SL, Berzofsky JA.
Clinical trial designs for the early clinical development of therapeutic cancer vaccines.
J Clin Oncol. 19: 1848-54, 2001.
107)  Wong EC, Maher VE, Hines K, Lee J, Carter CS, Goletz T, Kopp W, Mackall CL, Berzofsky J, Read EJ.
Development of a clinical-scale method for generation of dendritic cells from PBMC for use in cancer immunotherapy.
Cytotherapy. 3: 19-29, 2001.
108)  Cripe TP, Mackall CL.
Exploiting genetic alterations to design novel therapies for cancer.
Hematol Oncol Clin North Am. 15: 657-75, viii, 2001.
109)  Mackall CL, Helman LJ.
High-dose chemotherapy for rhabdomyosarcoma: where do we go from here.
J Pediatr Hematol Oncol. 23: 266-7, 2001.
110)  Mackall CL, Fry TJ, Bare C, Morgan P, Galbraith A, Gress RE.
IL-7 increases both thymic-dependent and thymic-independent T-cell regeneration after bone marrow transplantation.
Blood. 97: 1491-7, 2001.
111)  Merino ME, Navid F, Christensen BL, Toretsky JA, Helman LJ, Cheung NK, Mackall CL.
Immunomagnetic purging of Ewing's sarcoma from blood and bone marrow: quantitation by real-time polymerase chain reaction.
J Clin Oncol. 19: 3649-59, 2001.
112)  Fry TJ, Christensen BL, Komschlies KL, Gress RE, Mackall CL.
Interleukin-7 restores immunity in athymic T-cell-depleted hosts.
Blood. 97: 1525-33, 2001.
113)  Fry TJ, Mackall CL.
Interleukin-7: master regulator of peripheral T-cell homeostasis.
Trends Immunol. 22: 564-71, 2001.
114)  Weil RJ, Zhuang Z, Pack S, Kumar S, Helman L, Fuller BG, Mackall CL, Oldfield EH.
Intramedullary Ewing sarcoma of the spinal cord: consequences of molecular diagnostics. Case report.
J Neurosurg. 95: 270-5, 2001.
115)  Jankelevich S, Mueller BU, Mackall CL, Smith S, Zwerski S, Wood LV, Zeichner SL, Serchuck L, Steinberg SM, Nelson RP, Sleasman JW, Nguyen BY, Pizzo PA, Yarchoan R.
Long-term virologic and immunologic responses in human immunodeficiency virus type 1-infected children treated with indinavir, zidovudine, and lamivudine.
J Infect Dis. 183: 1116-20, 2001.
116)  Dagher R, Pham TA, Sorbara L, Kumar S, Long L, Bernstein D, Mackall C, Raffeld M, Tsokos M, Helman L.
Molecular confirmation of Ewing sarcoma.
J Pediatr Hematol Oncol. 23: 221-4, 2001.
117)  Kontny HU, Hämmerle K, Klein R, Shayan P, Mackall CL, Niemeyer CM.
Sensitivity of Ewing's sarcoma to TRAIL-induced apoptosis.
Cell Death Differ. 8: 506-14, 2001.
118)  Mackall CL.
Spreading the wealth: antigen discovery in adult tumors can help hone the search for pediatric tumor antigens.
J Immunother. 24: 281-2, 2001.
119)  Fry TJ, Mackall CL.
What limits immune reconstitution in HIV infection? Divergent tools converge on thymic function.
AIDS. 15: 1881-2, 2001.
120)  Mackall CL, Stein D, Fleisher TA, Brown MR, Hakim FT, Bare CV, Leitman SF, Read EJ, Carter CS, Wexler LH, Gress RE.
Prolonged CD4 depletion after sequential autologous peripheral blood progenitor cell infusions in children and young adults.
Blood. 96: 754-62, 2000.
121)  Mackall CL.
T-cell immunodeficiency following cytotoxic antineoplastic therapy: a review.
Stem Cells. 18: 10-8, 2000.
122)  Mackall CL, Helman LJ.
Targeting pediatric malignancies for T cell-mediated immune responses.
Curr Oncol Rep. 2: 539-46, 2000.
123)  Mackall C, Berzofsky J, Helman LJ.
Targeting tumor specific translocations in sarcomas in pediatric patients for immunotherapy.
Clin. Orthop. Relat. Res. 25-31, 2000.
124)  Mackall CL.
T-cell immunodeficiency following cytotoxic antineoplastic therapy: a review.
Oncologist. 4: 370-8, 1999.
125)  Kontny HU, Lehrnbecher TM, Chanock SJ, Mackall CL.
Simultaneous expression of Fas and nonfunctional Fas ligand in Ewing's sarcoma.
Cancer Res. 58: 5842-9, 1998.
126)  Mackall CL, Punt JA, Morgan P, Farr AG, Gress RE.
Thymic function in young/old chimeras: substantial thymic T cell regenerative capacity despite irreversible age-associated thymic involution.
Eur J Immunol. 28: 1886-93, 1998.
127)  Borkowski TA, Letterio JJ, Mackall CL, Saitoh A, Wang XJ, Roop DR, Gress RE, Udey MC.
A role for TGFbeta1 in langerhans cell biology. Further characterization of the epidermal Langerhans cell defect in TGFbeta1 null mice.
J Clin Invest. 100: 575-81, 1997.
128)  Hakim FT, Cepeda R, Kaimei S, Mackall CL, McAtee N, Zujewski J, Cowan K, Gress RE.
Constraints on CD4 recovery postchemotherapy in adults: thymic insufficiency and apoptotic decline of expanded peripheral CD4 cells.
Blood. 90: 3789-98, 1997.
129)  Mackall CL, Fleisher TA, Brown MR, Andrich MP, Chen CC, Feuerstein IM, Magrath IT, Wexler LH, Dimitrov DS, Gress RE.
Distinctions between CD8+ and CD4+ T-cell regenerative pathways result in prolonged T-cell subset imbalance after intensive chemotherapy.
Blood. 89: 3700-7, 1997.
130)  Borkowski TA, Letterio JJ, Mackall CL, Saitoh A, Farr AG, Wang XJ, Roop DR, Gress RE, Udey MC.
Langerhans cells in the TGF beta 1 null mouse.
Adv Exp Med Biol. 417: 307-10, 1997.
131)  Mackall CL, Gress RE.
Pathways of T-cell regeneration in mice and humans: implications for bone marrow transplantation and immunotherapy.
Immunol Rev. 157: 61-72, 1997.
132)  Mackall CL, Hakim FT, Gress RE.
Restoration of T-cell homeostasis after T-cell depletion.
Semin Immunol. 9: 339-46, 1997.
133)  Mackall CL, Hakim FT, Gress RE.
T-cell regeneration: all repertoires are not created equal.
Immunol Today. 18: 245-51, 1997.
134)  Lehrnbecher T, Foster C, Vázquez N, Mackall CL, Chanock SJ.
Therapy-induced alterations in host defense in children receiving therapy for cancer.
J Pediatr Hematol Oncol. 19: 399-417, 1997.
135)  Mackall CL, Gress RE.
Thymic aging and T-cell regeneration.
Immunol Rev. 160: 91-102, 1997.
136)  Letterio JJ, Geiser AG, Kulkarni AB, Dang H, Kong L, Nakabayashi T, Mackall CL, Gress RE, Roberts AB.
Autoimmunity associated with TGF-beta1-deficiency in mice is dependent on MHC class II antigen expression.
J Clin Invest. 98: 2109-19, 1996.
137)  Schwartz GN, Hakim F, Zujewski J, Szabo JM, Cepada R, Riseberg D, Warren MK, Mackall CL, Setzer A, Noone M, Cowan KH, O'Shaughnessy J, Gress RE.
Early suppressive effects of chemotherapy and cytokine treatment on committed versus primitive haemopoietic progenitors in patient bone marrow.
Br J Haematol. 92: 537-47, 1996.
138)  Mackall CL, Bare CV, Granger LA, Sharrow SO, Titus JA, Gress RE.
Thymic-independent T cell regeneration occurs via antigen-driven expansion of peripheral T cells resulting in a repertoire that is limited in diversity and prone to skewing.
J Immunol. 156: 4609-16, 1996.
139)  Mackall CL, Fleisher TA, Brown MR, Andrich MP, Chen CC, Feuerstein IM, Horowitz ME, Magrath IT, Shad AT, Steinberg SM.
Age, thymopoiesis, and CD4+ T-lymphocyte regeneration after intensive chemotherapy.
N Engl J Med. 332: 143-9, 1995.
140)  Ivy SP, Mackall CL, Gore L, Gress RE, Hartley AH.
Demodicidosis in childhood acute lymphoblastic leukemia; an opportunistic infection occurring with immunosuppression.
J Pediatr. 127: 751-4, 1995.
141)  Kulkarni AB, Ward JM, Yaswen L, Mackall CL, Bauer SR, Huh CG, Gress RE, Karlsson S.
Transforming growth factor-beta 1 null mice. An animal model for inflammatory disorders.
Am J Pathol. 146: 264-75, 1995.
142)  Christ M, McCartney-Francis NL, Kulkarni AB, Ward JM, Mizel DE, Mackall CL, Gress RE, Hines KL, Tian H, Karlsson S.
Immune dysregulation in TGF-beta 1-deficient mice.
J Immunol. 153: 1936-46, 1994.
143)  Mackall CL, Fleisher TA, Brown MR, Magrath IT, Shad AT, Horowitz ME, Wexler LH, Adde MA, McClure LL, Gress RE.
Lymphocyte depletion during treatment with intensive chemotherapy for cancer.
Blood. 84: 2221-8, 1994.
144)  Mackall CL, Granger L, Sheard MA, Cepeda R, Gress RE.
T-cell regeneration after bone marrow transplantation: differential CD45 isoform expression on thymic-derived versus thymic-independent progeny.
Blood. 82: 2585-94, 1993.
145)  Paradise NF, Surmitis JM, Mackall CL.
O2 reserve of left ventricle of isolated, saline-perfused rabbit heart.
Am J Physiol. 247: H861-8, 1984.
Click Here to View Collapsed Bibliography.

This page was last updated on 8/25/2013.